Novozymes to acquire Philom Bios Inc.

 | Source: Novonesis (Novozymes A/S) Novonesis (Novozymes A/S) 

Today Novozymes Biologicals Holding A/S, a wholly-owned subsidiary of Novozymes
A/S, (“Novozymes”), has signed a pre-acquisition agreement with Philom Bios
Inc. (“Philom Bios”), whereby Novozymes has agreed to offer the shareholders of
Philom Bios CAD 6.50 per share in cash. This represents a total equity value of
approximately CAD 25.6 million (DKK 138 million¹), corresponding to an
enterprise value to sales multiple of approximately 2.0, based on 2005/06
sales. The offer includes outstanding stock options. Novozymes does not
currently hold any stake in Philom Bios. 

Download the full stock exchange announcement

Attachments

2007_26_philom_bios_acquisition_uk.pdf
GlobeNewswire

Recommended Reading